Loncar Cancer Financial Statements From 2010 to 2024
| CNCR Etf | USD 14.19 0.37 2.68% |
Check Loncar Cancer financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Loncar Cancer's main balance sheet or income statement drivers, such as , as well as many indicators such as . Loncar financial statements analysis is a perfect complement when working with Loncar Cancer Valuation or Volatility modules.
Loncar |
Loncar Cancer Immunotherapy ETF Beta Analysis
Loncar Cancer's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Loncar Cancer Beta | 0.95 |
Most of Loncar Cancer's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Loncar Cancer Immunotherapy is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Loncar Cancer Immunotherapy has a Beta of 0.95. This is much higher than that of the Loncar Investments family and significantly higher than that of the Health category. The beta for all United States etfs is notably lower than that of the firm.
Loncar Cancer Immuno Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Loncar Cancer's current stock value. Our valuation model uses many indicators to compare Loncar Cancer value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Loncar Cancer competition to find correlations between indicators driving Loncar Cancer's intrinsic value. More Info.Loncar Cancer Immunotherapy is second largest ETF in price to earning as compared to similar ETFs. It is the top ETF in price to book as compared to similar ETFs fabricating about 0.08 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Loncar Cancer Immunotherapy is roughly 12.38 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Loncar Cancer by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Loncar Cancer Financial Statements
Loncar Cancer shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Loncar Cancer investors may analyze each financial statement separately, they are all interrelated. The changes in Loncar Cancer's assets and liabilities, for example, are also reflected in the revenues and expenses on on Loncar Cancer's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic focus on the development of drugs that harness the bodys own immune system to fight cancer. Loncar Cancer is traded on NASDAQ Exchange in the United States.
Pair Trading with Loncar Cancer
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Loncar Cancer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Loncar Cancer will appreciate offsetting losses from the drop in the long position's value.Moving together with Loncar Etf
| 0.64 | XLV | Health Care Select | PairCorr |
| 0.69 | VHT | Vanguard Health Care | PairCorr |
| 0.88 | IBB | iShares Biotechnology ETF | PairCorr |
| 0.83 | XBI | SPDR SP Biotech | PairCorr |
Moving against Loncar Etf
| 0.57 | MEME | Roundhill Investments | PairCorr |
| 0.47 | RSPY | Tuttle Capital Management | PairCorr |
| 0.41 | DSJA | DSJA | PairCorr |
| 0.36 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
The ability to find closely correlated positions to Loncar Cancer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Loncar Cancer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Loncar Cancer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Loncar Cancer Immunotherapy to buy it.
The correlation of Loncar Cancer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Loncar Cancer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Loncar Cancer Immuno moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Loncar Cancer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Loncar Cancer Correlation against competitors. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
The market value of Loncar Cancer Immuno is measured differently than its book value, which is the value of Loncar that is recorded on the company's balance sheet. Investors also form their own opinion of Loncar Cancer's value that differs from its market value or its book value, called intrinsic value, which is Loncar Cancer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Loncar Cancer's market value can be influenced by many factors that don't directly affect Loncar Cancer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Loncar Cancer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Loncar Cancer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Loncar Cancer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.